Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases.
Bacsur P, Resál T, Sarlós P, Iliás Á, Dalma Sümegi L, Kata D, Dávid A, Farkas B, Ivány E, Bálint A, Bősze Z, Fábián A, Bor R, Szepes Z, Afif W, Bessissow T, Farkas K, Lakatos PL, Molnár T.
Bacsur P, et al. Among authors: david a.
Therap Adv Gastroenterol. 2024 Oct 16;17:17562848241290636. doi: 10.1177/17562848241290636. eCollection 2024.
Therap Adv Gastroenterol. 2024.
PMID: 39464507
Free PMC article.